Lucid Diligence Brief: Mendra $82 million Series A to support AI-enabled rare-disease therapeutics
Lucid Diligence Brief: Mendra $82 million Series A to support AI-enabled…
Lucid Diligence Brief: Insilico and Hygtia partner on brain-penetrant NLRP3 inhibitor
Lucid Diligence Brief: Insilico and Hygtia partner on brain-penetrant NLRP3…
Lucid Diligence Brief: GSK to acquire RAPT Therapeutics
Lucid Diligence Brief: GSK to acquire RAPT Therapeutics Professional audiences…
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…
Lucid Diligence Brief: AstraZeneca to acquire Modella AI
Lucid Diligence Brief: AstraZeneca to acquire Modella AI Professional audiences…
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy…
Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in IBD
Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in……
Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s deal
Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s…
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in immuno-fibrotic disease space
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in…
Lucid Diligence Brief: Aurora Therapeutics launches to scale personalized CRISPR
Lucid Diligence Brief: Aurora Therapeutics launches to scale personalized…
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4 in COPD
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4…
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A Professional…